FAQ

trametinib dimethyl sulfoxide

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
01220132017

Related topics

Related topics

2 relations

Narrower (1)

Mekinist

Broader (1)

trametinib

Related mentions per year

Related mentions per year

2012-2018
201020122014201620182020
trametinib dimethyl sulfoxide
trametinib
Mekinist

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Running Title : Combination therapy of β-catenin RNAi and MEK inhibition β-catenin mRNA silencing and MEK inhibition display synergistic efficacy in preclinical tumor models
Colorectal carcinomas (CRC) harbor well-defined genetic abnormalities including aberrant activation of Wnt/β-catenin and MAPK… (More)
Is this relevant?
2017
2017
Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination.
In unresectable or metastatic melanoma with a BRAF V600 mutation, combined BRAF/MEK targeted therapy improves clinical outcomes… (More)
  • figure 1
Is this relevant?
Review
2015
Review
2015
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
IMPORTANCE The cutaneous adverse effects of the BRAF inhibitors vemurafenib and dabrafenib mesylate in the treatment of… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2013
2013
Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.
 
Is this relevant?